2024
The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer
Johnson K, Ni A, Quiroga D, Pariser A, Sudheendra P, Williams N, Sardesai S, Cherian M, Stover D, Gatti-Mays M, Ramaswamy B, Lustberg M, Jhawar S, Skoracki R, Wesolowski R. The survival benefit of adjuvant trastuzumab with or without chemotherapy in the management of small (T1mic, T1a, T1b, T1c), node negative HER2+ breast cancer. Npj Breast Cancer 2024, 10: 49. PMID: 38898072, PMCID: PMC11187074, DOI: 10.1038/s41523-024-00652-4.Peer-Reviewed Original ResearchInvasive disease-free survivalHER2+ breast cancerAdjuvant trastuzumabOverall survivalLocoregional therapyUnivariate analysisBreast cancerBenefit of adjuvant trastuzumabBenefits of adjuvant systemic therapyMulti-institutional retrospective analysisAdjuvant systemic therapyCompare survival outcomesDisease-free survivalTrastuzumab monotherapyNode-negativeSystemic therapyCombination therapySurvival benefitStatistically significant improvementSurvival outcomesRetrospective analysisMultivariate analysisPrimary outcomeTrastuzumabTherapyReal‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer
Sukumar J, Sardesai S, Ni A, Williams N, Johnson K, Quiroga D, Ramaswamy B, Wesolowski R, Cherian M, Stover D, Gatti‐Mays M, Pariser A, Sudheendra P, George M, Lustberg M. Real‐world treatment patterns of adjuvant endocrine therapy and ovarian suppression in premenopausal HR+/HER2+ breast cancer. Cancer Medicine 2024, 13: e7317. PMID: 38895891, PMCID: PMC11185945, DOI: 10.1002/cam4.7317.Peer-Reviewed Original ResearchConceptsOvarian suppressionEndocrine therapyAdjuvant endocrine therapyBreast cancerClinicopathological featuresAromatase inhibitorsOS useHR+/HER2+ breast cancerOptimal adjuvant endocrine therapyHuman epidermal growth factor receptor 2Epidermal growth factor receptor 2Real-world treatment patternsCohort of premenopausal womenAnti-HER2 therapyPremenopausal breast cancerClinicopathological risk factorsMultivariable logistic regression assessed associationsLogistic regression assessed associationsPremenopausal BCPrescribed tamoxifenPremenopausal patientsPremenopausal womenBC subtypesContemporary cohortAnti-HER2Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial
Worthen-Chaudhari L, Schnell P, Hackney M, Lustberg M. Partnered dance evokes greater intrinsic motivation than home exercise as therapeutic activity for chemotherapy-induced deficits: secondary results of a randomized, controlled clinical trial. Frontiers In Psychology 2024, 15: 1383143. PMID: 38962217, PMCID: PMC11220256, DOI: 10.3389/fpsyg.2024.1383143.Peer-Reviewed Original ResearchTherapeutic physical activityHome exercisesPhysical activitySurvivors of breast cancerSurvivors of cancerDance-based interventionsPartner dancePatient-reported outcomesRandomized controlled trialsIntrinsic motivationRandomized-controlled studyIntrinsic Motivation InventorySecondary analysisExerciseHealthy agingSocial danceSelf-determination theorySensorimotor function deficitsControlled clinical trialsDanceBreast cancerInterventionExtrinsic motivationMotivation InventoryNeuropathy diagnosisOutcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer.
Tarantino P, Lee D, Foldi J, Soulos P, Gross C, Grinda T, Winer E, Lin N, Krop I, Tolaney S, Lustberg M, Sammons S. Outcomes with trastuzumab deruxtecan (T-DXd) by HER2 status and line of treatment in a large real-world database of patients with metastatic breast cancer. Journal Of Clinical Oncology 2024, 42: 1077-1077. DOI: 10.1200/jco.2024.42.16_suppl.1077.Peer-Reviewed Original ResearchReal-world progression-free survivalLines of therapyMetastatic breast cancerMedian real-world progression-free survivalT-DXdHER2+Overall survivalHER2-lowHER2- patientsBreast cancerHER2- metastatic breast cancerTreat metastatic breast cancerProgression-free survivalKaplan-Meier methodLines of treatmentDatabase of patientsRetrospective observational studyClinical trial settingHER2 casesIHC 0Trastuzumab deruxtecanHR statusHER2 statusTriple-negativeMedian ageLong-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life
Proussaloglou E, Lustberg M. Long-Term Considerations for Young Breast Cancer Patients: Fertility, Sexual Health, and Quality of Life. Current Breast Cancer Reports 2024, 16: 227-236. DOI: 10.1007/s12609-024-00548-z.Peer-Reviewed Original ResearchYoung breast cancer patientsSurvivorship careBreast cancer patientsEffectiveness of cancer careFamily planning concernsPost-partum careUnique survivorship needsQuality-of-life issuesBreast cancerQuality of lifeCancer patientsSurvivorship needsGenitourinary syndrome of menopauseCancer careDisease-free recurrenceAnti-estrogen therapyUnique group of patientsSexual healthGroup of patientsCareVaginal estrogenEndocrine therapyOverall survivalSummaryAdditional researchIatrogenic menopauseThe Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life
Loeser A, Kim J, Peppercorn J, Burkard M, Niemierko A, Juric D, Kalinsky K, Rugo H, Glenn L, Hodgdon C, Maues J, Johnson S, Padron N, Parekh K, Lustberg M, Bardia A. The Right Dose: Results of a Patient Advocate–Led Survey of Individuals With Metastatic Breast Cancer Regarding Treatment-Related Side Effects and Views About Dosage Assessment to Optimize Quality of Life. JCO Oncology Practice 2024, 20: 972-983. PMID: 38518184, DOI: 10.1200/op.23.00539.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment-related side effectsSide effectsDose reductionBreast cancerLow dosesQuality of lifePhase I clinical trialFlexible dosing optionsMaximum tolerated doseDose of drugCourse of therapyIndividual doses of drugsCourse of treatmentPatient-physician discussionsPrescribed doseTolerated doseTargeted therapyDosing optionsAlternative dosingMedical oncologistsDose initiationHigh dosesImprove patient well-beingEffective treatmentRandomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial
Lustberg M, Fan-Havard P, Wong F, Hill K, Phelps M, Herrera K, Tsai N, Synold T, Feng Y, Kalu C, Sedrak M, Yee L. Randomized placebo-controlled, double-blind clinical trial of nanoemulsion curcumin in women with aromatase inhibitor-induced arthropathy: an Alliance/NCORP pilot trial. Breast Cancer Research And Treatment 2024, 205: 61-73. PMID: 38280052, PMCID: PMC11062803, DOI: 10.1007/s10549-023-07223-4.Peer-Reviewed Original ResearchAI-induced arthralgiaBrief Pain Inventory-Short FormRandomized placebo-controlledPostmenopausal womenPlacebo-controlledBreast cancerDouble-blind pilot trialDouble-blind clinical trialGrip strengthReduced risk of recurrenceDiscontinuation of treatmentRisk of recurrenceGastrointestinal adverse effectsPilot trialPlasma curcuminInflammation-related conditionsPatient-reported outcome measuresSerum estradiolWell-toleratedEstrone levelsPurposeAromatase inhibitorsTreatment armsRandomized trialsT0-T3Study agentsFeasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial
Buga A, Harper D, Sapper T, Hyde P, Fell B, Dickerson R, Stoner J, Kackley M, Crabtree C, Decker D, Robinson B, Krystal G, Binzel K, Lustberg M, Volek J. Feasibility and metabolic outcomes of a well-formulated ketogenic diet as an adjuvant therapeutic intervention for women with stage IV metastatic breast cancer: The Keto-CARE trial. PLOS ONE 2024, 19: e0296523. PMID: 38166036, PMCID: PMC10760925, DOI: 10.1371/journal.pone.0296523.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerStage IV metastatic breast cancerKetogenic dietInsulin resistanceNutritional ketosisPlasma insulinBreast cancerBody compositionAdjuvant therapeutic interventionsMetabolic outcomesCancer patientsPlasma glucoseMetabolic effectsBody fatShort-term studiesBody weightPleiotropic mechanismsTherapeutic interventionsConsistent bloodPhase IMonthsWomenCancerAd libitumChemotherapyAn Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer
Quiroga D, Wesolowski R, Zelinskas S, Pinette A, Benner B, Schwarz E, Savardekar H, Johnson C, Stiff A, Yu L, Macrae E, Lustberg M, Mrozek E, Ramaswamy B, Carson W. An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer. Cancer Control 2024, 31: 10732748241250189. PMID: 38797949, PMCID: PMC11129578, DOI: 10.1177/10732748241250189.Peer-Reviewed Original ResearchConceptsMetastatic HER2+ breast cancerHER2+ breast cancerStable diseaseBreast cancerCpG-ODNTrastuzumab treatmentTreated patientsHuman epidermal growth factor receptor 2 (HER2)-positiveToll-like receptor 9 agonistHER2-positive breast cancerWeek 2Immune profile changesPeripheral blood mononuclear cellsAdvanced/metastatic breast cancerVEGF-D levelsOpen-label phaseNK cell populationEfficacy of current treatmentsOpen-label studyAggressive breast cancerBlood mononuclear cellsCompared to baselineMedian PFSMetastatic HER2Monocytic MDSCs
2023
Post-diagnosis weight trajectories and mortality among women with breast cancer
Puklin L, Li F, Cartmel B, Zhao J, Sanft T, Lisevick A, Winer E, Lustberg M, Spiegelman D, Sharifi M, Irwin M, Ferrucci L. Post-diagnosis weight trajectories and mortality among women with breast cancer. Npj Breast Cancer 2023, 9: 98. PMID: 38042922, PMCID: PMC10693588, DOI: 10.1038/s41523-023-00603-5.Peer-Reviewed Original ResearchBody mass indexBreast cancer diagnosisWeight changeCause mortalityClinical characteristicsWeight gainWeight lossBreast cancerWeight trajectoriesPost-diagnosis weight changeBreast cancer-specific mortalityCox proportional hazards modelModern treatment eraCancer-specific mortalityCancer diagnosisModerate weight lossModerate weight gainProportional hazards modelAdverse health outcomesElectronic health recordsTreatment eraBaseline characteristicsTumor RegistryMass indexWeight managementPrevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study
Blansky D, Ansari N, Gao L, Sokol E, Sivakumar S, Huang R, Pelletier M, Levy M, Pavlick D, Danziger N, Ross J, Lustberg M, Rozenblit M. Prevalence of targetable genomic alterations in young women with advanced breast cancer: a cross-sectional study. Breast Cancer Research And Treatment 2023, 204: 181-185. PMID: 37999916, DOI: 10.1007/s10549-023-07179-5.Peer-Reviewed Original ResearchComprehensive genomic profilingBreast cancerYoung womenGenomic alterationsAdvanced breast cancerPD-L1 expressionTargetable genomic alterationsWorse clinical outcomesTime of diagnosisTumor mutational burdenCross-sectional studyBreast cancer casesFoundation MedicineClinical outcomesPIK3CA mutationsCancer casesEstrogen receptorMutational burdenOlder womenConclusionOur findingsTotal casesBreast tumorsTumor tissueBRCA1 mutationsMicrosatellite instabilityClinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study
Nagaraj G, Vinayak S, Khaki A, Sun T, Kuderer N, Aboulafia D, Acoba J, Awosika J, Bakouny Z, Balmaceda N, Bao T, Bashir B, Berg S, Bilen M, Bindal P, Blau S, Bodin B, Borno H, Castellano C, Choi H, Deeken J, Desai A, Edwin N, Feldman L, Flora D, Friese C, Galsky M, Gonzalez C, Grivas P, Gupta S, Haynam M, Heilman H, Hershman D, Hwang C, Jani C, Jhawar S, Joshi M, Kaklamani V, Klein E, Knox N, Koshkin V, Kulkarni A, Kwon D, Labaki C, Lammers P, Lathrop K, Lewis M, Li X, de Lima Lopes G, Lyman G, Makower D, Mansoor A, Markham M, Mashru S, McKay R, Messing I, Mico V, Nadkarni R, Namburi S, Nguyen R, Nonato T, O'Connor T, Panagiotou O, Park K, Patel J, Patel K, Peppercorn J, Polimera H, Puc M, Rao Y, Razavi P, Reid S, Riess J, Rivera D, Robson M, Rose S, Russ A, Schapira L, Shah P, Shanahan M, Shapiro L, Smits M, Stover D, Streckfuss M, Tachiki L, Thompson M, Tolaney S, Weissmann L, Wilson G, Wotman M, Wulff-Burchfield E, Mishra S, French B, Warner J, Lustberg M, Accordino M, Shah D. Clinical characteristics, racial inequities, and outcomes in patients with breast cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) cohort study. ELife 2023, 12: e82618. PMID: 37846664, PMCID: PMC10637772, DOI: 10.7554/elife.82618.Peer-Reviewed Original ResearchConceptsCOVID-19 severityWorse COVID-19 outcomesCOVID-19 outcomesBreast cancerCause mortalityCohort studyAcute respiratory syndrome coronavirus 2 infectionCOVID-19Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infectionRegistry-based retrospective cohort studyHistory of BCIntensive care unit admissionNon-Hispanic white patientsSyndrome coronavirus 2 infectionWorse ECOG performance statusMultivariable ordinal logistic regression modelsCare unit admissionCoronavirus 2 infectionECOG performance statusRetrospective cohort studyPacific Islander patientsCoronavirus disease 2019American Cancer SocietyLogistic regression modelsResearch grant supportP13-029-23 Cross-Sectional Associations of Serum Fatty Acids and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy
Melink Z, Schnell P, Ormiston K, Weinhold K, Kopec R, Lustberg M, Orchard T. P13-029-23 Cross-Sectional Associations of Serum Fatty Acids and Self-Reported Cognitive Outcomes in Women With Breast Cancer Undergoing Chemotherapy. Current Developments In Nutrition 2023, 7: 100485. DOI: 10.1016/j.cdnut.2023.100485.Peer-Reviewed Original ResearchIdentifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach.
Radwan R, Hertz D, Hickey E, Vachhani H, Lustberg M, Bridges J, Sabo R, Sheppard V, Salgado T. Identifying factors that influence the decision to reduce, delay, or discontinue treatment due to chemotherapy-induced peripheral neuropathy: A community-centered approach. Journal Of Clinical Oncology 2023, 41: e13123-e13123. DOI: 10.1200/jco.2023.41.16_suppl.e13123.Peer-Reviewed Original ResearchChemotherapy-induced peripheral neuropathyMetastatic breast cancerPeripheral neuropathyTreatment alterationsTreatment effectivenessMBC patientsCIPN symptomsMedical oncologistsDiscontinue treatmentClinical guidelinesOncology cliniciansCommunity-centered approachEffective therapyBreast cancerChemotherapy agentsTreatment decisionsPatient prioritiesPatient's perspectiveDose reductionAlternative treatmentOptimize outcomesPatientsSide effectsTreatment planHealthcare providersMetastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study.
Fanucci K, Lustberg M, Fischbach N, Pelletier M, Sivapiragasam A, Ashok Kumar P, Kallem M, Danziger N, Sokol E, Sivakumar S, Pavlick D, Ross J, Pusztai L. Metastatic breast cancer (MBC) with ultra-high tumor mutational burden (UHTMB): A comprehensive genomic profiling (CGP) study. Journal Of Clinical Oncology 2023, 41: 1036-1036. DOI: 10.1200/jco.2023.41.16_suppl.1036.Peer-Reviewed Original ResearchMetastatic breast cancerLobular histologyBreast cancerHER2 IHCGenomic alterationsComprehensive genomic profiling studyPD-L1 gene amplificationImmune checkpoint inhibitor treatmentMicrosatellite instabilityAxillary LN metastasisMetastatic site biopsySubset of ptsStage IV diseaseCheckpoint inhibitor treatmentPD-L1 expressionTumor mutational burdenMutations/MbMSI-high statusHER2 IHC resultsGenomic profiling studiesSite biopsiesSP142 assayLN metastasisMetastatic diseaseHigh TMBRetrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer.
Minta A, Rose L, Park C, Trovato S, Lustberg M, Sudheendra P, Cherian M, Gatti-Mays M, Stover D, Wesolowski R, Sardesai S, Ramaswamy B, Williams N, Dulmage B. Retrospective cohort study of CDK4/6-inhibitor-induced alopecia in patients with breast cancer. Journal Of Clinical Oncology 2023, 41: e13083-e13083. DOI: 10.1200/jco.2023.41.16_suppl.e13083.Peer-Reviewed Original ResearchBreast cancerEIA patientsDermatology referralsOnset of alopeciaRetrospective cohort studyMetastatic breast cancerRisk of alopeciaCyclin-dependent kinase 4Endocrine monotherapyOral minoxidilEndocrine therapyClinical improvementCohort studyRetrospective cohortFemale patientsTherapeutic optionsCombination therapyGrade severityTherapeutic responseFavorable outcomeAndrogenetic alopeciaDean scaleCDK4/6iPatientsSignificant improvementThe genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing.
Lustberg M, Kaneva K, Teslow E, Mauer E, Federman N, Eisfeld A. The genomic landscape of adolescent and young adult (AYA) malignancies using DNA and RNA-based next generation sequencing. Journal Of Clinical Oncology 2023, 41: e15091-e15091. DOI: 10.1200/jco.2023.41.16_suppl.e15091.Peer-Reviewed Original ResearchTriple-negative breast cancerTumor mutational burdenCancer patientsAYA patientsMicrosatellite instabilityBreast cancerNext-generation sequencingYoung adult cancer patientsYoung adult malignancyColorectal cancer patientsAdult cancer patientsHER2- breast cancerOlder adult patientsAYA cancer patientsSoft tissue sarcomasCentral nervous systemHigh-grade gliomasLow-grade gliomasPathogenic single nucleotide variantsAYA cancerSingle nucleotide variantsAdult patientsGastrointestinal malignanciesNTRK fusionsAML subgroupsA review of the impact of energy balance on triple-negative breast cancer
Akingbesote N, Owusu D, Liu R, Cartmel B, Ferrucci L, Zupa M, Lustberg M, Sanft T, Blenman K, Irwin M, Perry R. A review of the impact of energy balance on triple-negative breast cancer. JNCI Monographs 2023, 2023: 104-124. PMID: 37139977, DOI: 10.1093/jncimonographs/lgad011.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsTriple-negative breast cancerInterventional studyBreast cancerCancer treatmentClinical interventional studyClinical observationalImmune activationCancer outcomesCancer careClinical studiesOverall healthEnergy intakeNarrative reviewCancer cellsEnergy expenditureCancerTreatmentEnergy balanceOutcomesExerciseReviewDetrimental effectsImmunotherapyStudyIntakeCase Study in Chemotherapy-Induced Neuropathy: Tango Dance Improved Over-Ground Local Gait Stability
Glover N, WIlder J, Patrick S, Hackney M, Lustberg M, Worthen-Chaudhari L. Case Study in Chemotherapy-Induced Neuropathy: Tango Dance Improved Over-Ground Local Gait Stability. Archives Of Physical Medicine And Rehabilitation 2023, 104: e16. DOI: 10.1016/j.apmr.2022.12.044.Peer-Reviewed Original ResearchChemotherapy-induced neuropathyGait stability indexBreast cancerGait stabilityTango danceDynamic gait stabilityOncology outpatientsBC survivorsSteady-state gaitGait assessmentClinical utilityNeuromechanical functionNeuropathyBalance deficitsInterventionFurther studiesHuman applicationSurvivorsMovement variabilityWeeksTest assessmentAssessmentOutpatientsCancerPerson's resistanceEffect of Partnered Dance Intervention on Upper Extremity Outcomes for Breast Cancer Survivors With CIPN
Bland C, Worthen-Chaudhari L, Hackney M, Lustberg M, Crasta J. Effect of Partnered Dance Intervention on Upper Extremity Outcomes for Breast Cancer Survivors With CIPN. Archives Of Physical Medicine And Rehabilitation 2023, 104: e24. DOI: 10.1016/j.apmr.2022.12.067.Peer-Reviewed Original ResearchBreast cancer survivorsHand grip strengthGrip strengthCancer survivorsUpper extremity outcomesChemotherapy-induced neuropathyUpper extremity functionSenior Fitness TestCase seriesExtremity functionOutpatient oncologyBreast cancerJamar dynamometerMAIN OUTCOMEDance interventionDance-based interventionBalance deficitsFitness testsT-testCIPNTango danceInterventionSurvivorsOutcomesNeuropathy